

MOLECULAR CANCER THERAPEUTICS

TABLE OF CONTENTS

HIGHLIGHTS

1221 Selected Articles from This Issue

REVIEW

1223 In Like a Lamb; Out Like a Lion: Marching CAR T Cells Toward Enhanced Efficacy in B-ALL

A C Pouya Safarzadeh Kozani, Pooria Safarzadeh Kozani, and Roddy S. O'Connor

SMALL MOLECULE THERAPEUTICS

1234 Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST and Systemic Mastocytosis

A C Anu Gupta, Jarnail Singh, Alfonso García-Valverde, César Serrano, Daniel L. Flynn, and Bryan D. Smith

1246 Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma

Brent A. Willobee, Alexander A. Gaidarski, Austin R. Dosch, Jason A. Castellanos, Xizi Dai, Siddharth Mehra, Fanuel Messaggio, Supriya Srinivasan, Michael N. VanSaun, Nagaraj S. Nagathihalli, and Nipun B. Merchant

1257 Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress

A C Antje Lindemann, Ameeta A. Patel, Lin Tang, Noriaki Tanaka, Frederico O. Gleber-Netto, Mason D. Bartels, Li Wang, Daniel J. McGrail, Shiaw-Yih Lin, Steven J. Frank, Mitchell J. Frederick, Jeffrey N. Myers, and Abdullah A. Osman

LARGE MOLECULE THERAPEUTICS

1270 PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing Malignancies

Qing Sheng, Joseph A. D'Alessio, Daniel L. Menezes, Christopher Karim, Yan Tang, Angela Tam, Suzanna Clark, Chi Ying, Anu Connor, Keith G. Mansfield, Jean-Michel Rondeau, Majid Ghoddusi, Felipe C. Geyer, Jane Gu, Margaret E. McLaughlin, Rick Newcombe, GiNell Elliot, William R. Tschantz, Sylvie Lehmann, Christie P. Fanton, Kathy Miller, Thomas Huber, Katherine G. Rendahl, Ursula Jeffrey, Nancy K. Pryer, Emma Lees, Paul Kwon, Judith A. Abraham, Jason S. Damiano, and Tinya J. Abrams

1283 Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells

Mariko Ishibashi, Junichi Yamamoto, Takumi Ito, Hiroshi Handa, Mika Sunakawa-Kii, Koiti Inokuchi, Rimpei Morita, and Hideto Tamura

1295 Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti-PD-L1 Immunotherapy

Bin Yi, Hao Cheng, Dorota Wyczecowska, Qingzhao Yu, Li Li, Augusto C. Ochoa, Adam I. Riker, and Yaguang Xi

TABLE OF CONTENTS

TARGETING DRUG RESISTANCE

1305 **Blocking Wnt/ β -catenin Signal Amplifies Anti-PD-1 Therapeutic Efficacy by Inhibiting Tumor Growth, Migration, and Promoting Immune Infiltration in Glioblastomas**

Hui Zhang, Yongyan Bi, Yuxi Wei, Jiayang Liu, Kudelaidi Kuerban, and Li Ye

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

1316 ***BRAF*^{V600E} Mutation in Cell-Free DNA, Rather than in Lesion Tissues, at Diagnosis Is An Independent Prognostic Factor in Children with Langerhans Cell Histiocytosis**

Chan-Juan Wang, Lei Cui, Hong-Hao Ma, Dong Wang, Li Zhang, Hong-Yun Lian, Wei-Jing Li, Qing Zhang, Tian-You Wang, Zhi-Gang Li, and Rui Zhang

AC AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

Close-up view of the binding interface between PCA062 (light cyan/violet ribbon), a therapeutic antibody drug conjugate and its target protein antigen, human P-cadherin (gold ribbon), a cell surface glycoprotein highly expressed in several human malignancies. Glutamate E155, a central epitope residue, is unique to human P-cadherin, thus conferring this antibody exquisite selectivity in delivering its toxic payload to P-cadherin expressing cancer cells. Read the full manuscript by Sheng and colleagues on page 1270.

